APO-CEFPROZIL TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CEFPROZIL (CEFPROZIL MONOHYDRATE)

Disponible desde:

APOTEX INC

Código ATC:

J01DC10

Designación común internacional (DCI):

CEFPROZIL

Dosis:

250MG

formulario farmacéutico:

TABLET

Composición:

CEFPROZIL (CEFPROZIL MONOHYDRATE) 250MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

SECOND GENERATION CEPHALOSPORINS

Resumen del producto:

Active ingredient group (AIG) number: 0127613003; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2007-03-09

Ficha técnica

Page 1 of 27
PRODUCT MONOGRAPH
PR
APO-CEFPROZIL
Cefprozil Tablets
(cefprozil as cefprozil monohydrate)
250 mg and 500 mg cefprozil (on anhydrous basis)
USP
Antibiotic
APOTEX INC.
150 Signet Drive
Toronto, Ontario
DATE OF REVISION:
M9L 1T9
June 3, 2020
_Control Number: _235587
_ _
Page 2 of 27
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
8
OVERDOSAGE
........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 9
STORAGE AND STABILITY
...............................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 11
PART II: SCIENTIFIC INFORMATION
.............................................................................
12
PHARMACEUTICAL INFORMATION
...............................................................................
12
CLINICAL TRIALS
...............................................................................................................
13
MIC